Table 2 Overview of participant characteristics

Age (years)

Mean (SD)

69.2 (9.3)

Sex

Male n (%)

716 (49.9)

Female n (%)

718 (50.1)

Body Mass Index (kg/m²)

 < 18.5, n (%)

22 (1.5)

18.5- < 25, n (%)

432 (30.1)

 ≥ 25- < 30, n (%)

562 (39.2)

 ≥ 30- < 40, n (%)

382 (26.7)

 ≥ 40, n (%)

35 (2.4)

Smoking status

Current, n (%)

436 (30.4)

Former, n (%)

824 (57.5)

Never, n (%)

174 (12.1)

Medication class in primary inhaler

LABA, n (%)

112 (7.8)

LAMA, n (%)

385 (26.8)

LABA/LAMA, n (%)

357 (24.9)

LABA/LAMA/ICS, n (%)

63 (4.4)

ICS, n (%)

9 (0.6)

ICS/LABA, n (%)

506 (35.3)

Short-acting, n (%)

2 (0.1)

GOLD stage^a

n (% non-missing)

801 (55.9)

I, n (%)

189 (23.6)

II, n (%)

440 (54.9)

III, n (%)

139 (17.4)

IV, n (%)

33 (4.1)

Outcome measures

Clinical COPD Questionnaire (CCQ)

Mean (SD)

1.7 (1.1)

COPD Assessment Test (CAT)

Mean (SD)

13.6 (7.8)

Number of moderate exacerbations^b

0, n (%)

1,113 (77.6)

1, n (%)

167 (11.6)

2, n (%)

72 (5.0)

3, n (%)

37 (2.6)

 ≥ 4, n(%)

45 (3.1)

Number of severe exacerbations^b

0, n (%)

1,386 (96.7)

1, n (%)

38 (2.6)

2, n (%)

5 (0.3)

3, n (%)

2 (0.1)

 ≥ 4, n(%)

3 (0.2)